The insulin-like growth factors and insulin-signalling systems: an appealing target for breast cancer therapy?
There is compelling evidence from epidemiological studies in humans, as well as in vitro and in vivo experimental observations including transgenic animal models, for a role of the IGF/insulin signalling system in cancer tumourigenesis. In this review focused on breast cancer, we review the experimental evidence, discuss the cellular and molecular mechanisms of tumourigenicity by the IGFs and insulin and various possible therapeutic strategies based on the mechanisms discussed.
Gray
S G
SG
Receptor Biology Laboratory, Hagedorn Research Institute, Gentofte, Denmark. stvg@novonordisk.com
Stenfeldt Mathiasen
I
I
De Meyts
P
P
D000818:Animals; D030801:Animals, Genetically Modified; D001943:Breast Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D005260:Female; D006801:Humans; D007328:Insulin / Q000276:immunology / Q000502:physiology*; D009154:Mutation; D009857:Oncogenes; D011972:Receptor, Insulin / Q000235:genetics / Q000502:physiology; D015398:Signal Transduction / Q000502:physiology*; D013002:Somatomedins / Q000276:immunology / Q000502:physiology*
D007328:Insulin; D013002:Somatomedins; D011972:Receptor, Insulin